cause AIDS) and are not taking medicines for HIV at the same time, some HIV
treatments that they may take in the future may be less likely to work.
People are advised to get an HIV test before starting to take BARACLUDE and
anytime that there is a chance they were exposed to HIV. BARACLUDE will not
help HIV infection.
In some people, hepatitis B symptoms may get worse or become very
serious when they stop taking BARACLUDE. People should not stop BARACLUDE
without talking to their healthcare provider. Healthcare providers will
need to follow their patients and do blood tests to check the liver when
BARACLUDE is stopped. People should tell their healthcare provider if they
have or develop kidney problems because their healthcare provider may want
to do tests to see if a lower dose is needed.
Because BARACLUDE is removed from the body through the kidneys, a dose
adjustment may be required. Healthcare providers may want to perform tests
to determine whether a patient needs a lower dose or should take BARACLUDE
less often than once a day.
It is not known if BARACLUDE(R) (entecavir) is safe to use during
pregnancy. It is not known if BARACLUDE helps to prevent a pregnant mother
from passing HBV to her baby. A pregnant woman and her healthcare provider
will need to decide if BARACLUDE is right for her. A woman should not
breastfeed if she is taking BARACLUDE.
People should discuss with their healthcare provider all prescription
and non-prescription medicines, vitamins, herbal supplements, and other
health preparations they are taking or plan to take. BARACLUDE may interact
with medicines that leave the body through the kidneys. The safety and
effectiveness of BARACLUDE in liver transplant recipients is unknown. The
most common side effects of BARACLUDE in clinical studies were headache,
tiredness, dizziness, and nausea.
This list of side effects is not complete at this time because
BARACLUDE is still under study. People should re
Page: 1 2 3 4 5 6 7 Related medicine technology :1
|SOURCE Bristol-Myers Squibb Company|
Copyright©2008 PR Newswire.
All rights reserved
. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients2
. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis3
. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer4
. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma5
. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma6
. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis7
. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia8
. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)9
. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma10
. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache11
. Many Heart Attack Patients Dont Get Best Emergency Treatment